Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ociperlimab - BeiGene

Next Previous
X
Search
Drug Profile

Ociperlimab - BeiGene

Alternative Names: Anti-TIGIT monoclonal antibody - BeiGene; BGB-A1217; WCD-118

Latest Information Update: 07 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BeiGene
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Cervical cancer; Liver cancer; Small cell lung cancer; Squamous cell cancer
  • Phase I/II Diffuse large B cell lymphoma
  • Phase I Solid tumours

Most Recent Events

  • 07 Oct 2024 BeiGene completes a phase II trial in Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease, Combination therapy) in Australia, Austria, China, France, Spain, South Korea and USA (IV) (NCT05014815)
  • 30 Aug 2024 BeiGene completes a phase I/II trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (IV) (NCT05267054)
  • 07 Aug 2024 Ociperlimab is still in phase I trials for Solid tumours (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Combination therapy, Second-line therapy or greater) in USA, Australia, China and Taiwan (IV) (NCT04047862)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top